Live Chat ×
Skip to main content

Microsampling—How it Can Influence Drug Development

Thank you

This live web event has ended. Thank you for attending.

Contributors

  • Neil Spooner, Ph.D. (Spooner Bioanalytical Solutions Ltd)

    Neil is the Founder and Director of Spooner Bioanalytical Solutions, a consultancy based in Hertford, UK. In this role, Neil helps companies to integrate microsampling of biological fluids into pre-clinical, clinical and bioanalytical workflows. He also works with innovator companies to help them develop novel microsampling and microanalytical technologies and introduce them to the market. Neil is also a Senior Visiting Research Fellow at the School of Life and Medical Sciences, University of Hertfordshire (Hertfordshire, UK), the Senior Editor of Bioanalysis Journal and the Deputy-Chair and Secretary of the Reid Bioanalytical Forum. He has published extensively, with over 60 peer reviewed manuscripts and more than 40 podium presentations at International Conferences and Symposia.

    Neil has extensive experience in the quantitative bioanalysis of drugs, metabolites and biomarkers in the pharmaceutical industry and contract research organisations in the UK and USA. In over 20 years of industrial practice at GlaxoSmithKline, he has led groups operating in the discovery and regulated arenas of clinical and pre-clinical quantitative bioanalysis and metabolite identification. Neil has extensive experience of successfully leading inter departmental and cross functional initiatives, including implementation of new technologies and workflows (such as microsampling), outsourcing quantitative bioanalysis, development and implementation of automation approaches and design of new scientific facilities.

  • Prajakti Kothare, Ph.D. (Merck Research Laboratories)

    Prajakti Kothare (Ph.D.) is Executive Director, Quantitative Pharmacology and Pharmacometrics within Pharmacokinetics, Pharmacodynamics and Drug Metabolism at Merck. As part of this role she provides strategic, personnel and portfolio oversight for translational and quantitative aspects of Infectious Diseases, Cardiometabolic and Opthalmics programs from discovery through life-cycle management. Prajakti is an experienced pharmaceutical research leader with a proven track record of portfolio and regulatory impact across multiple therapeutic areas and across modalities. 

    Since joining Merck in 2011, Prajakti has assumed leadership positions of increasing responsibility. Prajakti has played a critical leadership role in building quantitative translational sciences at Merck. Prajakti has been instrumental in driving efforts aimed at modernizing clinical trials such as the application of dried blood spots, digital health and home-sampling in clinical trials resulting in faster, efficient decisions. From 2001-2011, while at Eli Lilly and Company (Global Pharmacokinetics and Pharmacodynamics), she was significantly involved in the development and registration of multiple drugs. Prajakti received a Bachelor’s degree in Pharmaceutical Sciences from the University of Bombay, India and a Ph.D. in Pharmaceutics (with a specialization in PKPD) from the University of Minnesota.

February 1, 2018
Thu 12:30 PM EST

Duration 1H 30M

This live web event has ended.